Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 55 entries
Sorted by: Best Match Show Resources per page
Endoscopic application of n-butyl-2-cyanoacrylate on esophagojejunal anastomotic leak: a case report.

Journal of medical case reports

Pramateftakis MG, Vrakas G, Kanellos I, Mantzoros I, Angelopoulos S, Eleftheriades E, Lazarides C.
PMID: 21392389
J Med Case Rep. 2011 Mar 10;5:96. doi: 10.1186/1752-1947-5-96.

INTRODUCTION: This case report describes an esophagojejunal anastomotic leak following total gastrectomy for gastric cancer. The leak was treated successfully with endoscopic application of n-butyl-2-cyanoacrylate. This is the first case report on the endoscopic application of cyanoacrylate alone for...

Cite
Pramateftakis MG, Vrakas G, Kanellos I, et al. Endoscopic application of n-butyl-2-cyanoacrylate on esophagojejunal anastomotic leak: a case report. J Med Case Rep. 2011;5:96doi: 10.1186/1752-1947-5-96.
Pramateftakis, M. G., Vrakas, G., Kanellos, I., Mantzoros, I., Angelopoulos, S., Eleftheriades, E., & Lazarides, C. (2011). Endoscopic application of n-butyl-2-cyanoacrylate on esophagojejunal anastomotic leak: a case report. Journal of medical case reports, 596. https://doi.org/10.1186/1752-1947-5-96
Pramateftakis, Manousos-Georgios, et al. "Endoscopic application of n-butyl-2-cyanoacrylate on esophagojejunal anastomotic leak: a case report." Journal of medical case reports vol. 5 (2011): 96. doi: https://doi.org/10.1186/1752-1947-5-96
Pramateftakis MG, Vrakas G, Kanellos I, Mantzoros I, Angelopoulos S, Eleftheriades E, Lazarides C. Endoscopic application of n-butyl-2-cyanoacrylate on esophagojejunal anastomotic leak: a case report. J Med Case Rep. 2011 Mar 10;5:96. doi: 10.1186/1752-1947-5-96. PMID: 21392389; PMCID: PMC3064650.
Copy Download .nbib Format: NLM
Fournier's Gangrene: Lessons Learned from Multimodal and Multidisciplinary Management of Perineal Necrotizing Fasciitis.

Frontiers in surgery

Ioannidis O, Kitsikosta L, Tatsis D, Skandalos I, Cheva A, Gkioti A, Varnalidis I, Symeonidis S, Savvala NA, Parpoudi S, Paraskevas GK, Pramateftakis MG, Kotidis E, Mantzoros I, Tsalis KG.
PMID: 28740847
Front Surg. 2017 Jul 10;4:36. doi: 10.3389/fsurg.2017.00036. eCollection 2017.

BACKGROUND: Fournier's gangrene (FG) is a rapidly evolving necrotizing fasciitis of the perineum and the genital area, the scrotum as it most commonly affects man in the vast majority of cases. It is polymicrobial in origin, due to the...

Cite
Ioannidis O, Kitsikosta L, Tatsis D, et al. Fournier's Gangrene: Lessons Learned from Multimodal and Multidisciplinary Management of Perineal Necrotizing Fasciitis. Front Surg. 2017;4:36doi: 10.3389/fsurg.2017.00036.
Ioannidis, O., Kitsikosta, L., Tatsis, D., Skandalos, I., Cheva, A., Gkioti, A., Varnalidis, I., Symeonidis, S., Savvala, N. A., Parpoudi, S., Paraskevas, G. K., Pramateftakis, M. G., Kotidis, E., Mantzoros, I., & Tsalis, K. G. (2017). Fournier's Gangrene: Lessons Learned from Multimodal and Multidisciplinary Management of Perineal Necrotizing Fasciitis. Frontiers in surgery, 436. https://doi.org/10.3389/fsurg.2017.00036
Ioannidis, Orestis, et al. "Fournier's Gangrene: Lessons Learned from Multimodal and Multidisciplinary Management of Perineal Necrotizing Fasciitis." Frontiers in surgery vol. 4 (2017): 36. doi: https://doi.org/10.3389/fsurg.2017.00036
Ioannidis O, Kitsikosta L, Tatsis D, Skandalos I, Cheva A, Gkioti A, Varnalidis I, Symeonidis S, Savvala NA, Parpoudi S, Paraskevas GK, Pramateftakis MG, Kotidis E, Mantzoros I, Tsalis KG. Fournier's Gangrene: Lessons Learned from Multimodal and Multidisciplinary Management of Perineal Necrotizing Fasciitis. Front Surg. 2017 Jul 10;4:36. doi: 10.3389/fsurg.2017.00036. eCollection 2017. PMID: 28740847; PMCID: PMC5502266.
Copy Download .nbib Format: NLM
Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK.

Metabolism: clinical and experimental

Valanti EK, Dalakoura-Karagkouni K, Fotakis P, Vafiadaki E, Mantzoros CS, Chroni A, Zannis V, Kardassis D, Sanoudou D.
PMID: 34875308
Metabolism. 2021 Dec 04;127:154954. doi: 10.1016/j.metabol.2021.154954. Epub 2021 Dec 04.

INTRODUCTION: Atherosclerotic Coronary Artery Disease (ASCAD) is the leading cause of mortality worldwide. Novel therapeutic approaches aiming to improve the atheroprotective functions of High Density Lipoprotein (HDL) include the use of reconstituted HDL forms containing human apolipoprotein A-I (rHDL-apoA-I)....

Cite
Valanti EK, Dalakoura-Karagkouni K, Fotakis P, et al. Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. Metabolism. 2021;127:154954doi: 10.1016/j.metabol.2021.154954.
Valanti, E. K., Dalakoura-Karagkouni, K., Fotakis, P., Vafiadaki, E., Mantzoros, C. S., Chroni, A., Zannis, V., Kardassis, D., & Sanoudou, D. (2021). Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. Metabolism: clinical and experimental, 127154954. https://doi.org/10.1016/j.metabol.2021.154954
Valanti, Eftaxia-Konstantina, et al. "Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK." Metabolism: clinical and experimental vol. 127 (2021): 154954. doi: https://doi.org/10.1016/j.metabol.2021.154954
Valanti EK, Dalakoura-Karagkouni K, Fotakis P, Vafiadaki E, Mantzoros CS, Chroni A, Zannis V, Kardassis D, Sanoudou D. Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. Metabolism. 2021 Dec 04;127:154954. doi: 10.1016/j.metabol.2021.154954. Epub 2021 Dec 04. PMID: 34875308.
Copy Download .nbib Format: NLM
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Metabolism: clinical and experimental

Polyzos SA, Kountouras J, Mantzoros CS.
PMID: 30502373
Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29.

The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple steatosis (SS), but also with advanced disease, i.e., nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis...

Cite
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018;92:82-97doi: 10.1016/j.metabol.2018.11.014.
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: clinical and experimental, 9282-97. https://doi.org/10.1016/j.metabol.2018.11.014
Polyzos, Stergios A, et al. "Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics." Metabolism: clinical and experimental vol. 92 (2019): 82-97. doi: https://doi.org/10.1016/j.metabol.2018.11.014
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29. PMID: 30502373.
Copy Download .nbib Format: NLM
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.

Molecular metabolism

Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A.
PMID: 32673798
Mol Metab. 2021 Aug;50:101049. doi: 10.1016/j.molmet.2020.101049. Epub 2020 Jul 13.

OBJECTIVE: The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFLD/NASH) is increasing. NAFLD/NASH may progress to cirrhosis and hepatocellular carcinoma. However, most patients with NAFLD/NASH will die from a vascular cause. There are no approved pharmacological treatments...

Cite
Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, et al. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab. 2020;50:101049doi: 10.1016/j.molmet.2020.101049.
Mahjoubin-Tehran, M., De Vincentis, A., Mikhailidis, D. P., Atkin, S. L., Mantzoros, C. S., Jamialahmadi, T., & Sahebkar, A. (2021). Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular metabolism, 50101049. https://doi.org/10.1016/j.molmet.2020.101049
Mahjoubin-Tehran, Maryam, et al. "Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis." Molecular metabolism vol. 50 (2021): 101049. doi: https://doi.org/10.1016/j.molmet.2020.101049
Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab. 2021 Aug;50:101049. doi: 10.1016/j.molmet.2020.101049. Epub 2020 Jul 13. PMID: 32673798; PMCID: PMC8324680.
Copy Download .nbib Format: NLM
The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis.

Hepatology communications

Perakakis N, Joshi A, Peradze N, Stefanakis K, Li G, Feigh M, Veidal SS, Rosen G, Fleming M, Mantzoros CS.
PMID: 32923834
Hepatol Commun. 2020 Jul 28;4(9):1302-1315. doi: 10.1002/hep4.1558. eCollection 2020 Sep.

CHS-131 is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic effects and less fluid retention and weight gain compared to thiazolidinediones in phase II clinical trials. We investigated the effects of CHS-131 on metabolic parameters and liver histopathology...

Cite
Perakakis N, Joshi A, Peradze N, et al. The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatol Commun. 2020;4(9):1302-1315doi: 10.1002/hep4.1558.
Perakakis, N., Joshi, A., Peradze, N., Stefanakis, K., Li, G., Feigh, M., Veidal, S. S., Rosen, G., Fleming, M., & Mantzoros, C. S. (2020). The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatology communications, 4(9), 1302-1315. https://doi.org/10.1002/hep4.1558
Perakakis, Nikolaos, et al. "The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis." Hepatology communications vol. 4,9 (2020): 1302-1315. doi: https://doi.org/10.1002/hep4.1558
Perakakis N, Joshi A, Peradze N, Stefanakis K, Li G, Feigh M, Veidal SS, Rosen G, Fleming M, Mantzoros CS. The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatol Commun. 2020 Jul 28;4(9):1302-1315. doi: 10.1002/hep4.1558. eCollection 2020 Sep. PMID: 32923834; PMCID: PMC7471426.
Copy Download .nbib Format: NLM
Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.

Endocrine reviews

Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS.
PMID: 34698815
Endocr Rev. 2021 Oct 26; doi: 10.1210/endrev/bnab034. Epub 2021 Oct 26.

Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the discovery of several promising drug targets and novel therapeutic strategies to address the global obesity epidemic and its comorbidities. Current pharmacologic options for obesity management are...

Cite
Angelidi AM, Belanger MJ, Kokkinos A, et al. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev. 2021;doi: 10.1210/endrev/bnab034.
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2021). Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocrine reviews, . https://doi.org/10.1210/endrev/bnab034
Angelidi, Angeliki M, et al. "Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy." Endocrine reviews vol. (2021). doi: https://doi.org/10.1210/endrev/bnab034
Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev. 2021 Oct 26; doi: 10.1210/endrev/bnab034. Epub 2021 Oct 26. PMID: 34698815.
Copy Download .nbib Format: NLM
Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity.

International journal of molecular medicine

Toumba M, Fanis P, Vlachakis D, Neocleous V, Phylactou LA, Skordis N, Mantzoros CS, Pantelidou M.
PMID: 34821371
Int J Mol Med. 2022 Jan;49(1). doi: 10.3892/ijmm.2021.5065. Epub 2021 Nov 25.

Severe early‑onset obesity is mainly attributed to single gene variations of the hypothalamic leptin‑melanocortin system, which is critical for controlling the balance between appetite and energy expenditure. Adenylate cyclase 3 (ADCY3), a transmembrane enzyme localized in primary neuronal cilia,...

Cite
Toumba M, Fanis P, Vlachakis D, et al. Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity. Int J Mol Med. 2021;49(1)doi: 10.3892/ijmm.2021.5065.
Toumba, M., Fanis, P., Vlachakis, D., Neocleous, V., Phylactou, L. A., Skordis, N., Mantzoros, C. S., & Pantelidou, M. (2022). Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity. International journal of molecular medicine, 49(1), . https://doi.org/10.3892/ijmm.2021.5065
Toumba, Meropi, et al. "Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity." International journal of molecular medicine vol. 49,1 (2022). doi: https://doi.org/10.3892/ijmm.2021.5065
Toumba M, Fanis P, Vlachakis D, Neocleous V, Phylactou LA, Skordis N, Mantzoros CS, Pantelidou M. Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity. Int J Mol Med. 2022 Jan;49(1). doi: 10.3892/ijmm.2021.5065. Epub 2021 Nov 25. PMID: 34821371; PMCID: PMC8651229.
Copy Download .nbib Format: NLM
CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.

International journal of obesity (2005)

Gkouskou KG, Georgiopoulos G, Vlastos I, Lazou E, Chaniotis D, Papaioannou TG, Mantzoros CS, Sanoudou D, Eliopoulos AG.
PMID: 34564706
Int J Obes (Lond). 2022 Jan;46(1):162-168. doi: 10.1038/s41366-021-00972-6. Epub 2021 Sep 25.

BACKGROUND/OBJECTIVES: Evidence regarding the influence of coffee on appetite and weight control is equivocal and the influence of covariates, such as genetic variation in caffeine metabolism, remains unknown. Herein, we addressed the novel hypothesis that genetic variation in CYP1A2,...

Cite
Gkouskou KG, Georgiopoulos G, Vlastos I, et al. CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. Int J Obes (Lond). 2021;46(1):162-168doi: 10.1038/s41366-021-00972-6.
Gkouskou, K. G., Georgiopoulos, G., Vlastos, I., Lazou, E., Chaniotis, D., Papaioannou, T. G., Mantzoros, C. S., Sanoudou, D., & Eliopoulos, A. G. (2022). CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. International journal of obesity (2005), 46(1), 162-168. https://doi.org/10.1038/s41366-021-00972-6
Gkouskou, Kalliopi G, et al. "CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study." International journal of obesity (2005) vol. 46,1 (2022): 162-168. doi: https://doi.org/10.1038/s41366-021-00972-6
Gkouskou KG, Georgiopoulos G, Vlastos I, Lazou E, Chaniotis D, Papaioannou TG, Mantzoros CS, Sanoudou D, Eliopoulos AG. CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. Int J Obes (Lond). 2022 Jan;46(1):162-168. doi: 10.1038/s41366-021-00972-6. Epub 2021 Sep 25. PMID: 34564706.
Copy Download .nbib Format: NLM
Daily transient coating of the intestine leads to weight loss and improved glucose tolerance.

Metabolism: clinical and experimental

Lo T, Lee Y, Tseng CY, Hu Y, Connelly MA, Mantzoros CS, Karp JM, Tavakkoli A.
PMID: 34687727
Metabolism. 2022 Jan;126:154917. doi: 10.1016/j.metabol.2021.154917. Epub 2021 Oct 21.

INTRODUCTION: Roux-en-Y gastric bypass surgery (RYGB) has been shown to be the gold standard treatment for obesity associated type-2-diabetes (T2D), however many T2D patients do not qualify or are reluctant to proceed with surgery due to its potential risks...

Cite
Lo T, Lee Y, Tseng CY, et al. Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism. 2021;126:154917doi: 10.1016/j.metabol.2021.154917.
Lo, T., Lee, Y., Tseng, C. Y., Hu, Y., Connelly, M. A., Mantzoros, C. S., Karp, J. M., & Tavakkoli, A. (2022). Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism: clinical and experimental, 126154917. https://doi.org/10.1016/j.metabol.2021.154917
Lo, Tammy, et al. "Daily transient coating of the intestine leads to weight loss and improved glucose tolerance." Metabolism: clinical and experimental vol. 126 (2022): 154917. doi: https://doi.org/10.1016/j.metabol.2021.154917
Lo T, Lee Y, Tseng CY, Hu Y, Connelly MA, Mantzoros CS, Karp JM, Tavakkoli A. Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism. 2022 Jan;126:154917. doi: 10.1016/j.metabol.2021.154917. Epub 2021 Oct 21. PMID: 34687727; PMCID: PMC8666968.
Copy Download .nbib Format: NLM
The-2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects.

Hormones (Athens, Greece)

Yiannakouris N, Melistas L, Yannakoulia M, Mungal K, Mantzoros CS.
PMID: 17003027
Hormones (Athens). 2003 Oct-Dec;2(4):229-36. doi: 10.14310/horm.2002.11104.

A common -2548G/A promoter variant of the human leptin gene has recently been shown to be associated with variations in circulating leptin levels but available data are still conflicting. The aim of this study was to explore potential associations...

Cite
Yiannakouris N, Melistas L, Yannakoulia M, et al. The-2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects. Hormones (Athens). 2003;2(4):229-36doi: 10.14310/horm.2002.11104.
Yiannakouris, N., Melistas, L., Yannakoulia, M., Mungal, K., & Mantzoros, C. S. (2003). The-2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects. Hormones (Athens, Greece), 2(4), 229-36. https://doi.org/10.14310/horm.2002.11104
Yiannakouris, Nikos, et al. "The-2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects." Hormones (Athens, Greece) vol. 2,4 (2003): 229-36. doi: https://doi.org/10.14310/horm.2002.11104
Yiannakouris N, Melistas L, Yannakoulia M, Mungal K, Mantzoros CS. The-2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects. Hormones (Athens). 2003 Oct-Dec;2(4):229-36. doi: 10.14310/horm.2002.11104. PMID: 17003027.
Copy Download .nbib Format: NLM
The rise of biosimilars: How they got here and where they are going.

Metabolism: clinical and experimental

Patel D, Gillis C, Naggar J, Mistry A, Mantzoros CS.
PMID: 28939017
Metabolism. 2017 Oct;75:45-53. doi: 10.1016/j.metabol.2017.07.008. Epub 2017 Aug 07.

Biosimilars have become a subject of great interest in the past few years. The European Union and the United States are seeing an increasing number of biosimilar applications and approvals. The development of a biosimilar is significantly more complex...

Cite
Patel D, Gillis C, Naggar J, et al. The rise of biosimilars: How they got here and where they are going. Metabolism. 2017;75:45-53doi: 10.1016/j.metabol.2017.07.008.
Patel, D., Gillis, C., Naggar, J., Mistry, A., & Mantzoros, C. S. (2017). The rise of biosimilars: How they got here and where they are going. Metabolism: clinical and experimental, 7545-53. https://doi.org/10.1016/j.metabol.2017.07.008
Patel, Dhiren, et al. "The rise of biosimilars: How they got here and where they are going." Metabolism: clinical and experimental vol. 75 (2017): 45-53. doi: https://doi.org/10.1016/j.metabol.2017.07.008
Patel D, Gillis C, Naggar J, Mistry A, Mantzoros CS. The rise of biosimilars: How they got here and where they are going. Metabolism. 2017 Oct;75:45-53. doi: 10.1016/j.metabol.2017.07.008. Epub 2017 Aug 07. PMID: 28939017.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 55 entries